IT-901

产品编号:Bellancom-124179| CAS NO:1584121-99-2| 分子式:C17H14N2O4S| 分子量:342.37

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,

货号 包装 价格 库存与货期 购买量 操作
Bellancom-124179
3500.00 杭州 北京(现货)
Bellancom-124179
5600.00 杭州 北京(现货)

增值税发票√顺丰快递√订货电话:18601927057

IT-901

产品介绍 IT-901 是一种具有口服活性且有效的 NF-κB 亚基 c-Rel 抑制剂,对 NF-κB 和 c-Rel 与 DNA 结合的 IC50 分别为 0.1 µM,3 μM。IT-901 是一种具有生物活性的萘硫代巴比妥酸酯衍生物,具有用于人类淋巴瘤和改善移植物抗宿主病 (GVHD) 的潜力。
生物活性

IT-901 is an orally active and potent NF-κB subunit c-Rel inhibitor with an IC50 of 0.1 µM, 3 μM for NF-κB DNA binding and c-Rel DNA binding, respectively. IT-901, a bioactive naphthalenethiobarbiturate derivative, has the potential for human lymphoid tumors and ameliorate graft-versus-host disease (GVHD).

体外研究

IT-901 (1, 3, 5 μM; for 24 hours) results in decreased proliferation of viable ABC and GCB DLBCL cells.
IT-901 (3 μM; for 24 hours) decreases cell viability in a dose-dependent fashion, at least 60 percent of cells were still viable after 48 hours of IT-901 treatment (4μM) in all tested cell lines except HBL1.
IT-901 (1, 5, 10 μM; for 6 hours) documents Diminished expression of p65 and p50 in nuclear and cytosolic fractions and also decreases the expression of the inhibitory subunit IκBα both in the phosphorylated and non-phosphorylated forms in primary CLL cells and cell lines.
The IC50 of IT-901/GDM-12 is 2.9 μM for c-Rel whereas IL-2 secretion is successfully blocked at 5 μM.
The concentrations of IT-901 above 10 μM become increasingly toxic and may lead to apoptosis of healthy cells.
IT-901 inhibits cell growth of both activated B-like (ABC) and germinal center B-like (GCB) cell lines with the IC50 values between 3μM to 4μM.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line: TMD8 and SU-DHL8 cells
Concentration: 1, 3, 5 μM
Incubation Time: For 24 hours
Result: Resulted in decreased proliferation of viable ABC and GCB DLBCL cells.

Cell Viability Assay

Cell Line: SU-DHL8 and TMD8 cells
Concentration: 3 μM
Incubation Time: For 24 hours
Result: Decreased cell viability in a dose-dependent fashion.

Western Blot Analysis

Cell Line: Primary chronic lymphocytic leukemia (CLL) cells and cell lines
Concentration: 1, 5, 10 μM
Incubation Time: For 6 hours
Result: Documented Diminished expression of p65 and p50 in nuclear and cytosolic fractions and also decreased the expression of the inhibitory subunit IκBα both in the phosphorylated and non-phosphorylated forms.
体内研究
(In Vivo)

IT-901 (24 mg/kg; IP; every other day for 2 weeks) has an effective treatment of acute GVHD without impairing anti-tumor activity.
IT-901 (12-20 mg/kg; IP) improves the PK profile by increasing T1/2 and Cmax.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/C-Tg (NFkB-RE-luc)-Xen mice with 6-9 weeks old
Dosage: 24 mg/kg
Administration: IP; every other day for 2 weeks
Result: Had an effective treatment of acute GVHD without impairing anti-tumor activity.
体内研究

IT-901 (24 mg/kg; IP; every other day for 2 weeks) has an effective treatment of acute GVHD without impairing anti-tumor activity.
IT-901 (12-20 mg/kg; IP) improves the PK profile by increasing T1/2 and Cmax.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/C-Tg (NFkB-RE-luc)-Xen mice with 6-9 weeks old
Dosage: 24 mg/kg
Administration: IP; every other day for 2 weeks
Result: Had an effective treatment of acute GVHD without impairing anti-tumor activity.
体内研究

IT-901 (24 mg/kg; IP; every other day for 2 weeks) has an effective treatment of acute GVHD without impairing anti-tumor activity.
IT-901 (12-20 mg/kg; IP) improves the PK profile by increasing T1/2 and Cmax.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/C-Tg (NFkB-RE-luc)-Xen mice with 6-9 weeks old
Dosage: 24 mg/kg
Administration: IP; every other day for 2 weeks
Result: Had an effective treatment of acute GVHD without impairing anti-tumor activity.
性状Solid
溶解性数据
In Vitro: 

DMSO : 12.5 mg/mL (36.51 mM; ultrasonic and warming and heat to 60°C)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.9208 mL 14.6041 mL 29.2082 mL
5 mM 0.5842 mL 2.9208 mL 5.8416 mL
10 mM 0.2921 mL 1.4604 mL 2.9208 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
参考文献

相关文档

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

相关产品


服务热线

13911702513
18601927057

微信客服